© 1999 by Oxford University Press
Journal of the National Cancer Institute, Vol. 91, No. 22, 1922-1932,
November 17, 1999
© 1999 Oxford University Press
REVIEW |
Mutational Spectra of PTEN/MMAC1 Gene: a Tumor Suppressor With Lipid Phosphatase Activity
Affiliations of authors: I. U. Ali, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD; L. M. Schriml, M. Dean, Laboratory of Genomic Diversity, National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, MD.
Correspondence to: Iqbal U. Ali, Ph.D., National Institutes of Health, Executive Plaza North, Rm. 201, Bethesda, MD 20892-7332 (e-mail: ia1t{at}nih.gov).
 |
ABSTRACT |
|---|
 Top Abstract IntroductionI. Germline PTEN/MMAC1 Mutations...II. Inactivation of PTEN/MMAC1...III. PTEN/MMAC1 as Tumor...NotesReferences |
|---|
PTEN/MMAC1 (phosphatase, tensin homologue/mutated in multiple advanced cancers) is a tumor suppressor protein that has sequence homology with dual-specificity phosphatases, which are capable of dephosphorylating both tyrosine phosphate and serine/threonine phosphate residues on proteins. The in vivo function of PTEN/MMAC1 appears to be dephosphorylation of phosphotidylinositol 3,4,5-triphosphate. The PTEN/MMAC1 gene is mutated in the germline of patients with rare autosomal dominant cancer syndromes and in subsets of specific cancers. Here we review the mutational spectra of the PTEN/MMAC1 gene in tumors from various tissues, especially endometrium, brain, prostate, and ovary, in which the gene is inactivated very frequently. Germline and somatic mutations in the PTEN/MMAC1 gene occur mostly in the protein coding region and involve the phosphatase domain and poly(A)6 stretches. Compared with germline alterations found in the PTEN/MMAC1 gene, there is a substantially increased frequency of frameshift mutations in tumors. Glioblastomas and endometrial carcinomas appear to have distinct mutational spectra, probably reflecting differences in the underlying mechanisms of inactivation of the PTEN/MMAC1 gene in the two tissue types. Also, depending on the tissue type, the gene appears to be involved in the initiation or the progression of cancers. Further understanding of PTEN/MMAC1 gene mutations in different tumors and the physiologic consequences of these mutations is likely to open up new therapeutic opportunities for targeting this critical gene.
|
INTRODUCTION |
|---|
|
TopAbstractIntroductionI. Germline PTEN/MMAC1 Mutations...II. Inactivation of PTEN/MMAC1...III. PTEN/MMAC1 as Tumor...NotesReferences |
|---|
Genetic alterations in a variety of critical genes underlie the formation and progression of human cancers. Some of these genes, such as tumor suppressors p53 (also known as TP53), Rb (retinoblastoma protein), and p16, are involved in central processes, such as transcriptional modulation and cell cycle regulation, and are frequently mutated in human cancers. Inactivation of another tumor suppressor gene PTEN/MMAC1 (phosphatase, tensin homologue/mutated in multiple advanced cancers) has been reported in several types of human tumors, including those from brain, breast, endometrium, kidney, and prostate (1-3). The name PTEN reflects the presence of the protein tyrosine phosphatase domain as well as the domain with homology to tensin. MMAC1 conveys the fact that the gene is mutated in multiple advanced cancers. Considerable information has accumulated within the last year on the mutations in the PTEN/MMAC1 gene in a wide variety of human cancers. In this review, we present the mutational spectra of the PTEN/MMAC1 gene in the germline as well as in tumors of various tissue types. The information was searched in the English language literature by use of the MEDLINE® database. We briefly discuss the enzymatic function of PTEN/MMAC1 with the purpose of understanding possible associations between distinct mutations and functional changes in specific malignancies.
PTEN/MMAC1 is located on chromosome 10q23.3 and encodes a predicted protein product of 403 amino acids containing a protein tyrosine phosphatase domain with a critical motif, IHCKAGKGRTG, found in dual specificity phosphatases (1-3), which dephosphorylate tyrosine as well as serine and threonine residues. The protein also has extensive identity to two cytoskeletal proteins—tensin, which appears to interact with actin filaments in focal adhesions, and auxilin, which is involved in synaptic vesicle transport (1-3). Mapping of homozygous deletions on chromosome 10q23 followed by representational difference analysis and positional cloning led to the isolation of the gene independently by two groups (1,2). Another approach utilized the conserved sequence motifs of phosphatases to isolate a novel protein tyrosine phosphatase, which turned out to be identical with PTEN/MMAC1 and whose transcription was modulated by transforming growth factor-ß (TGF-ß), giving the protein another name, TEP1 (TGF-ß-regulated and epithelial cell-enriched phosphatase) (3).
Three lines of evidence have established PTEN/MMAC1 as a tumor suppressor gene. First, germline mutations in PTEN/MMAC1 are associated with autosomal dominant hamartomatous and often cancer-predisposing syndromes, Cowden's disease and Bannayan-Zonana syndrome (see Section I). Second, the PTEN/MMAC1 gene is homozygously inactivated in a variety of sporadic human cancers (see Section II). Third, it is a highly conserved protein, with phosphatase activity capable of dephosphorylating tyrosine and serine/threonine residues of proteins as well as position 3 on the inositol ring of the lipid phosphatidylinositol 3,4,5-triphosphate (PIP3). Introduction of the PTEN/MMAC1 gene into cancer cell lines leads to growth suppression, and the heterozygous or homozygous inactivation of the gene in the mouse germline results in increased tumor susceptibility or embryonic lethality, respectively (see Section III).
|
I. GERMLINE PTEN/MMAC1 MUTATIONS IN PATIENTS WITH HAMARTOMA SYNDROMES AND PREDISPOSITION TO CANCERS |
|---|
|
TopAbstractIntroductionI. Germline PTEN/MMAC1 Mutations...II. Inactivation of PTEN/MMAC1...III. PTEN/MMAC1 as Tumor...NotesReferences |
|---|
The hamartomatous polyposis syndromes, Cowden's disease (Mendelian Inheritance in Man [MIM] database No. 158350), Bannayan-Zonana syndrome (MIM No. 153480), and juvenile polyposis coli (MIM No. 174900), are rare autosomal dominant disorders with the common feature of the development of hamartomas, which are hyperplastic, disorganized, and nonmalignant growths. All three syndromes appear to have distinct clinical features as well as partial overlap in their clinical phenotype. The predominant phenotype of Cowden's disease is hamartomas of the skin; other organ sites developing hamartomas include breast, thyroid, endometrium, gastrointestinal tract, and central nervous system, with breast cancers developing in 25%-50% of affected women and thyroid cancer in 3%-10% of affected individuals (4,5). Lhermitte-Duclos disease, which is characterized by an unusual central nervous system tumor, cerebellar dysplastic gangliocytoma, is also associated with Cowden's disease (6). Juvenile polyposis coli patients develop hamartomatous polyps of the digestive tract and are reported to be predisposed to gastrointestinal cancer and possibly to pancreatic cancer (7), whereas in the case of Bannayan-Zonana syndrome, no definite documentation exists regarding an increased risk of malignancy (8).
Germline mutations in the PTEN/MMAC1 gene have been detected in Cowden's disease and in Bannayan-Zonana syndrome families (9-25). In juvenile polyposis coli syndrome, however, the presence of PTEN/MMAC1 germline mutations has been controversial (26,27) for multiple reasons, including overlap of phenotypic features with Cowden's disease and Bannayan-Zonana syndrome, age-related penetrance of the disease, and genetic heterogeneity (28,29). Recently, linkage for juvenile polyposis coli was established on the chromosomal region 18q21.1 (30), and germline mutations in the SMAD4 tumor suppressor gene were detected in a subset of juvenile polyposis coli families (31).
The frequency and types of mutations reported in multiple studies in Cowden's disease
and in Bannayan-Zonana syndrome families are shown in Fig. 1.
Of the 95
germline mutations reported, 25 are frameshift mutations and the rest are point mutations
comprising 35 nonsense mutations, 24 missense mutations, and 11 base substitutions generating
splice variants. Altogether, 75% of the germline mutations corresponding to nonsense,
frameshift, and splice-site mutations result in the generation of a truncated protein. A very high
proportion of the missense mutations, 13 (54%) of 24, cluster in the phosphatase core
motif beween residues 122 and 132 in exon 5, altering primarily glycine 129 and arginine 130. A
similar proportion, 19 (54%) of 35 nonsense mutations, target three codons, 130 and 157
in exon 5 and 233 in exon 7 of the PTEN/MMAC1 gene. Residue 233 is altered by nonsense
mutations in one Bannayan-Zonana syndrome and in five Cowden's disease families (9,11,14,15).
|
A relatively low frequency or even absence of PTEN/MMAC1 mutations in some Cowden's disease and Bannayan-Zonana syndrome (10,22,32) patients has been reported, suggesting genetic heterogeneity. Nevertheless, the germline mutations reported so far argue that, in most Cowden's disease families and in a subset of Bannayan-Zonana syndrome families, PTEN/MMAC1 is the susceptibility gene and that these hamartomatous polyposis syndromes are allelic to each other. Furthermore, deletion of the wild-type allele of the PTEN/MMAC1 gene detected in the DNAs from hamartomas of various organs analyzed in Cowden's disease patients and from normal tissues adjacent to the tumors indicates that loss of its expression is an early event leading to increased proliferation, tissue disorganization, and susceptibility to tumor development (11,14). This contention is strongly supported by the recent observation that mice with germline heterozygous mutations in PTEN/MMAC1 develop increased susceptibility to tumors of various tissues (33-35).
|
II. INACTIVATION OF PTEN/MMAC1 GENE IN MULTIPLE HUMAN TUMORS |
|---|
|
TopAbstractIntroductionI. Germline PTEN/MMAC1 Mutations...II. Inactivation of PTEN/MMAC1...III. PTEN/MMAC1 as Tumor...NotesReferences |
|---|
Besides the germline mutations in inherited hamartomatous syndromes, somatic mutations in the PTEN/MMAC1 gene are frequently found in a variety of sporadic human tumors in which the wild-type allele of the gene is inactivated mostly by deletions, thus conforming to the classical paradigm of tumor suppressor genes. The region on chromosome 10q that harbors the PTEN/MMAC1 gene and very likely other tumor suppressor gene(s) is hemizygously deleted in many human cancers, with a frequency reaching 60%-80% in the case of prostate cancer, endometrial carcinoma, and advanced glial tumors. Studies carried out within the last year have established PTEN/MMAC1 as the likely target gene of these deletions in many human tumors. The gene is inactivated by multiple mechanisms, including homozygous genomic deletions. In tumors with hemizygous deletions at chromosome 10q23, frameshift or nonsense mutations or mutations resulting in splice variants prematurely terminate the open reading frame of the remaining copy of the gene, thus producing a truncated and nonfunctional protein. Alternatively, the remaining copy of the gene is altered by missense mutations that are predicted to severely impair the function of its protein product. A detailed analysis of the nature and frequency of PTEN/MMAC1 gene mutations in different cancers may provide insights into the underlying genetic mechanisms of tumorigenesis in specific tissue types.
Endometrial Cancer
Endometrial carcinoma is the second most common noncolonic malignancy in hereditary nonpolyposis colon cancer (HNPCC) families, whose members carry germline mutations in mismatch repair genes resulting in replication errors and microsatellite instability (36). Among sporadic endometrial cancers, microsatellite instability is present only at a frequency of 20% (37). The two histologic variants of endometrial carcinoma, the endometrioid and serous types, appear to carry distinct genetic lesions. The less common but more aggressive serous carcinoma harbors mutations in the p53 gene with about 90% frequency, whereas K-ras mutations are restricted to the endometrioid type and are present in 20% of the tumors (38,39).
Several reports (39-45) show that PTEN/MMAC1 is the most
frequently mutated gene identified yet in endometrial cancers. Inactivation of the PTEN/MMAC1
gene appears to be confined to tumors of endometrioid histology. In six different studies analyzing
a total of 286 tumors (39-45), PTEN/MMAC1 mutations were detected
in 33%-55% of the endometrial cancers, the highest frequency among the different
tumor types examined so far (Table 1). Furthermore, PTEN/MMAC1
mutations occur in early well-differentiated lesions (stage I/grade 1) as well as in very advanced
and invasive tumors (stage IV/grade 3), suggesting their involvement in the initiation of
endometrial tumorigenesis. That the inactivation of the PTEN/MMAC1 gene is an early event in
endometrial carcinogenesis is also supported by data from two independent studies (46,47) showing a 22% frequency of PTEN/MMAC1 mutations in premalignant
lesions of endometrial hyperplasia both with and without atypia.
|
Other striking features of the mutational profile of PTEN/MMAC1 in endometrial cancer are the substantially high frequency of mutations in microsatellite instability-positive tumors (78%-86%) compared with the microsatellite instability-negative tumors (
30%) as well as the relative abundance of frameshift mutations (Fig. 2, A). It is not clear if the elevated frequency of frameshift mutations in endometrial
carcinoma is a manifestation of the tumor's microsatellite instability-positive phenotype. A
causal relationship is believed to exist between defective mismatch repair systems and alterations
in microsatellite sequences in HNPCC (36). DNA polymerase slippage
events at microsatellite repeat sequences lead to misalignment of DNA strands, which, if not
repaired, give rise to deletions or insertions, resulting in frameshift mutations (48). However, the mutations in the PTEN/MMAC1 gene in endometrial carcinoma do
not appear to be a consequence of a generalized replication error phenotype, as suggested by the
following observations: 1) The frequency of mutations in the known DNA repair genes in
endometrial carcinomas appears to be very low, 2) the repeat sequence in the transforming
growth factor receptor BII gene, which is almost always mutated in microsatellite
instability-positive colon cancers, is rarely mutated in endometrial cancers (49), and 3) the mutational spectrum of the PTEN/MMAC1 gene in microsatellite
instability-negative endometrioid tumors does not differ from that in microsatellite
instability-positive tumors (40,41). These observations argue that the
PTEN/MMAC1 gene may be specifically targeted for mutations in endometrial carcinoma and is
necessary for tumorigenesis.
|
Malignant Glial Tumors
Evolution of glioblastomas, the highest malignancy grade glial tumors of the brain, is believed to occur via multiple genetic pathways. Notably, two pathways for which the molecular details are well characterized (50) are readily discernible in the formation of malignant gliomas. One subset of glioblastomas evolves from low-grade gliomas, which commonly harbor p53 mutations, via a progression pathway accumulating multiple genetic lesions that often include loss of chromosome 10 sequences. Alternatively, glioblastomas can develop in a de novo fashion following epidermal growth factor receptor amplification and gene losses on chromosome 10. Thus, loss of heterozygosity on chromosome 10 is a characteristic feature of high-malignancy-grade gliomas arising via both genetic pathways and occurs in 60%-80% of the tumors (50). PTEN/MMAC1 appears to be one of the target genes on chromosome 10 in glioblastomas and is found to be mutated in combination with either p53 mutations or epidermal growth factor receptor amplification (51). However, in many glioblastomas, the PTEN/MMAC1 gene is inactivated without accompanying alterations in either p53 or epidermal growth factor receptor genes. Thus, amplification of epidermal growth factor receptor, which harbors a receptor tyrosine kinase activity, and mutations in PTEN/MMAC1, with an associated phosphatase activity, appear to be independent of each other (51,52).
A total of 674 malignant glial tumors (anaplastic astrocytomas and glioblastomas multiforme) were analyzed, and PTEN/MMAC1 mutations were reported in 159 of these tumors, i.e., at a frequency of 24% (1,2,51-63). That PTEN/MMAC1 is not the only target for inactivation on chromosome 10 in gliomas is suggested by the fact that a considerable fraction of tumors with allelic losses on chromosome 10 retain a normal copy of the gene. Deletion mapping as well as functional studies have provided evidence for the presence of multiple tumor suppressor genes on both arms of chromosome 10 that may be involved in the development of glial neoplasms of different malignancy grades (64). Another putative tumor suppressor gene, DMBT1 (deleted in malignant brain tumors) with homology to the scavenger receptor cysteine-rich superfamily, has been identified on chromosome 10q25.3-26.1, which appears to be homozygously deleted in a subset of glioblastomas (65).
The spectrum of somatic mutations in the PTEN/MMAC1 gene in glioblastomas encompasses
insertions, deletions, and point mutations, with the latter constituting about 60% of total
mutations (Fig. 2,
B). It is not clear if this mutational profile is
attributable to alterations in the mismatch repair genes. Glioblastomas have been reported to be
weakly microsatellite instability positive (66), and an association appears
to exist between reduced levels of expression of multiple mismatch repair genes and tumor
progression (67). It has been reported that MSH6, along with MSH2,
functions in repairing single-base mismatches and smaller insertions/deletions and that cells
derived from MSH6-deficient mice have a single nucleotide mismatch repair defect (68). Molecular profiling of the mismatch repair genes, in particular MSH6, in
glioblastomas would be helpful in understanding the mutational spectrum of PTEN/MMAC1 with
a relative abundance of base substitutions, a feature characteristic so far of the p53 gene, as
opposed to frameshift mutations.
Prostate Carcinoma
Deletion mapping analysis of chromosome 10 in prostate carcinoma
identified a complex pattern of allelic losses that includes 10q23.3,
the region where the PTEN/MMAC1 gene resides (69). Analysis of
200 primary prostate carcinomas and 71 metastases from multiple sites,
including those from pelvic lymph nodes, revealed 16 homozygous
deletions and 10 mutations (70-74) (Table 1; Fig.
2, C). Of
these, 13 (18%) tumors with homozygous deletions or point mutations
derived from 71 metastases. The rather low frequency of mutations
(10%) in primary and metastatic prostate carcinoma, which included
both homozygous deletions and intragenic mutations, could be due to
several factors. First, loss of the PTEN/MMAC1 gene may be particularly
relevant to the progression and metastasis of advanced prostate
carcinomas, a conclusion suggested by two studies (70,71).
Second, tumors were not always screened for homozygous deletions and
there may be a higher frequency of homozygous deletions than reported.
Finally, the possibility exists that inactivation of the PTEN/MMAC1
gene occurs by mechanisms other than deletions and mutations. In this
context, loss of expression or reduced expression of PTEN/MMAC1, both
at the messenger RNA and protein levels, was recently demonstrated in
xenografted prostate tumors (75). Restoration of PTEN/MMAC1
expression by demethylation in cells derived from the xenografts
suggests loss of expression by promoter methylation (75).
However, this mode of inactivation requires further exploration, since
promoter methylation of the PTEN/MMAC1 gene could not be detected in
prostate tumors with allelic loss of the gene and wild-type sequence of
the remaining copy (70).
Ovarian Tumors
Epithelial ovarian tumors exist as four major histologic types
(endometrioid, serous, mucinous, and clear cell), which probably evolve
via distinct molecular pathways. Analysis of all four histologic types
of ovarian tumors for the loss of heterozygosity on chromosome 10 and
mutations in the PTEN/MMAC1 gene indicated that the gene is mutated
predominantly, if not exclusively, in ovarian tumors of endometrioid
origin (76,77). Although allelic losses on chromosome 10 were
common in both endometrioid (43%) and serous (28%) tumors, PTEN/MMAC1
mutations were detected only in endometrioid ovarian tumors with a 26%
frequency (Table 1) and in one of the 10 mucinous tumors examined that
displayed a mixed mucinous and endometrioid histology. Thus, an
important observation is that PTEN/MMAC1 mutations are common in
endometrial as well as ovarian tumors of endometrioid histology and
that tumors of both types containing such mutations are well or
moderately differentiated, suggesting the involvement of PTEN/MMAC1
tumor suppressor function in disease initiation.
Other Cancers
Approximately 25%-50% of women with Cowden's disease develop
breast cancers (5,6). It was, therefore, of interest to
determine if PTEN/MMAC1 is involved in the pathogenesis of sporadic
breast tumors. Screening of the PTEN/MMAC1 gene in 116 primary breast
tumors, most of which included stage I and II tumors, showed an
extremely low frequency of mutations (5%) (53,78,79) (Table
1). It is conceivable that PTEN/MMAC1 is inactivated mainly in advanced
and metastatic breast tumors (79), as is the case in glial and
prostatic tumors. It is, however, also possible that different subsets
of genes are involved in sporadic versus inherited breast cancers, as
is suggested by the absence of mutations in sporadic tumors of BRCA1
and BRCA2 genes responsible for inherited breast cancer in a number of
pedigrees (80).
Thyroid cancer is also among the clinical manifestations of Cowden's disease. In an initial screen of 95 sporadic thyroid tumors encompassing many histologic types, one frameshift mutation in a papillary thyroid carcinoma was detected (81). It is possible that inactivation of the gene is associated with a particular histologic type. Alternatively, the gene may be inactivated in some tumor types by mechanisms other than mutations in the coding region.
Genetic alterations in the PTEN/MMAC1 gene were reported in seven of 67 head and neck
squamous cell carcinomas (53,82,83), in one of eight kidney cancers (53), in four of 99 lung carcinomas (53,84-86), in
three of 27 melanomas (53,87), in one of 29 gastric carcinomas (41), and in three of 68 lymphomas (88,89)
examined (Table 1). Although the PTEN/MMAC1 gene is very frequently
inactivated in high-malignancy-grade gliomas, mutations in the gene were detected at a much
lower frequency in many other types of brain tumors (52,55,56,59-61,63,90). Of the 427 brain tumors of various types examined, including low-grade
astrocytomas, pilocytic astrocytomas, medulloblastomas, oligodendrogliomas, oligoastrocytomas,
and meningiomas, PTEN/MMAC1 alterations were detected only in seven tumors. Similarly,
PTEN/MMAC1 appears to play a role in the development of endometrial and ovarian tumors of
endometrioid histology, but mutations were not detected in other tumors of the female genital
tract, such as the serous type of ovarian and endometrial tumors and squamous cervical carcinoma
(40,76,77,91). Thus, the data obtained so far suggest that inactivation of
the PTEN/MMAC1 gene is relevant in the formation of tumors of specific histology and tissue
type.
Distribution of Mutations in PTEN/MMAC1 Gene
We have compiled PTEN/MMAC1 mutations in a variety of cancers
reported through May 1999. In a total of about 2300 tumors analyzed and
sequenced, 374 inactivating mutations, which include 44 homozygous
deletions, have been reported (Table 1). Many tumor types were not
examined specifically for homozygous deletions of the PTEN/MMAC1 gene
or for mutations in the regulatory sequences; therefore, the overall
mutation frequency of 16% may be an underestimation. Although the
mutations are scattered over the entire gene, clustering of missense
mutations in exons 5 and 6 (Fig. 2, D), of nonsense mutations in exon 7
(Fig. 2, E), and of frameshift mutations in and around the
poly(A)6 stretches and phosphorylation sites in exon 7 and
especially in exon 8 (Fig. 2, F) is obvious. The phosphatase domain
located in exon 5 is the target of missense mutations. Most striking is
the observation that the phosphatase core motif that constitutes less
than 3% of the gene is the site of about 31% and 23% of point
mutations reported so far in germline and sporadic tumors,
respectively. A vast majority of germline mutations (74%) are point
mutations compared with 51% of the somatic mutations detected in
various tumors (two-sided P<.00003; Fisher's exact test );
in particular, nonsense mutations are substantially elevated in the
germline. In contrast, 49% of the inactivating mutations in the
PTEN/MMAC1 gene in tumors were frameshift mutations versus 26% in the
germline (Table 2).
|
Among the missense mutations, transitions and transversions occur with about equal frequency. Altogether, 50 base substitutions in tumors result in a termination codon, and 22 of these (i.e., 44%) occur in three codons containing the dinucleotide CpG. There are nine codons containing CpG dinucleotides in the PTEN/MMAC1 open reading frame, three of which occur as CGA at codons 130, 233, and 335. The cytosine residue in these three codons is frequently mutated to thymine, thus terminating the open reading frame at the stop codon. Ten tumors had mutations at codon 130, which is located in the phosphatase core motif, and eight and four tumors each were mutated at codons 233 and 335, respectively. Another CpG dinucleotide present in codon 173 as CGC is mutated in 12 tumors; in eight of those tumors, the cytosine is replaced by thymine, resulting in the substitution of arginine for cysteine. This is consistent with the observation that frequent methylation of cytosine residues in CpG dinucleotides renders them prone to spontaneous deamination and a consequent C to T transition that occurs at a much higher rate than in unmethylated bases (92). The spectrum of point mutations in human tumors as well as in the germline also indicates that about one third of all base substitutions occur at a CpG dinucleotide.
Most of the PTEN/MMAC1 mutations were detected in glioblastomas and endometrial,
ovarian, and prostate carcinomas. The mutational spectrum appears to have characteristic features
for the tumors of each tissue type. In endometrial carcinoma, 60% of the mutations are
frameshift versus 37% in glioblastomas (two-sided P<.0004; Fisher's
exact test) (Table 2). Most of these frameshift mutations are 1-4 base
pairs (bp) in length and occur predominantly in the N-terminal region of the gene or in exons 7
and 8, which contain potential tyrosine and/or serine phosphorylation sites (Fig. 2, A). Most notably, 15 single-base frameshift mutations (seven insertions and eight
deletions of A) are clustered within the poly(A)6 stretch in codons 321-323 and nine
tumors sustained a loss of 4 bp at the palindromic repeat sequence (TACTTACTTTA) at codons
317-320 (Fig. 2, A). Similarly, at another poly(A)6 stretch
between codons 265-267, there was a loss of a single A in six tumors. One of the mechanisms for
the generation of short deletions and insertions involves mispairing of the DNA strands at repeat
sequences. Mononucleotide runs are believed to be the site of slipped misalignment of the
template DNA strand, resulting in deletion or insertion if the nucleotide(s) excluded from pairing
is on the template or primer strand, respectively. There is a clustering of missense mutations (23
[77%] of 30 missense mutations) in exon 5 and nonsense mutations (10
[45%] of 22 nonsense mutations) in exon 7 (Fig. 2, A).
The mutational spectrum of PTEN/MMAC1 in glioblastomas is distinct from that in
endometrial carcinomas. In comparison with endometrial tumors, glioblastomas exhibit
substantially fewer frameshift alterations but more missense mutations (Table 2; Fig. 2, B). This may reflect a different role for
PTEN/MMAC1 in these two tumor types and/or differences in the mechanisms of mutation. Of
the 150 mutations reported, 94 are single-base substitutions (i.e., 63% versus 40%
in endometrial carcinoma), generating 61 missense, 21 nonsense, and 12 splice site variants (Table
2). Conspicuously, 17 mutations are clustered between codons 170 and
codon 173 in exon 6, 10 of which (one frameshift and nine missense mutations) target codon 173,
which contains one of the nine CpG sites of the gene and encodes for a highly conserved residue.
Mutations reported in various other cancers are shown in Fig. 2, C.
Although the numbers are small, about 72% of the mutations (26 of 36) result in truncation
of the protein. Five of the nine mutations reported in ovarian carcinoma are in the phosphatase
core motif, four of them targeting codon 130.
The codons most frequently and differentially targeted by both germline as well as somatic
mutations are listed in Table 3. Codons 129 and 130, which are located in
the phosphatase core motif, are mutated at much higher frequencies in the germline than in
various tumors. Codon 157, which is probably important for stabilizing the tertiary structure of
the protein, is mutated in four Cowden's disease families but is not altered in any of the
tumors. Of the four codons containing CpG dinucleotides that are frequently mutated in the
germline and/or tumors, codon 130 is in the phosphatase core motif; 173 is conserved in tensin,
auxilin, and bacterial phosphatase (2,3); and codons 233 and 335 are
within or near tyrosine and/or serine phosphorylation sites. One striking feature is that codon 173
and its neighboring residues are predominantly mutated in glioblastomas with nine of the 12 point
mutations occurring in glial tumors. Analysis of the enzymatic as well as tumor suppressor
functions of the PTEN/MMAC1 protein mutated at codon 173 and elucidation of its signaling
pathways in glial cells would be helpful in understanding the significance of mutational targeting
of Arg 173 in glioblastomas.
|
The most obvious difference between the germline and somatic mutations is a very high density of somatic frameshift mutations at and around the two poly(A)6 stretches encompassing codons 265-267 and especially between codons 321 and 323, which is directly preceded by a palindromic sequence and a tyrosine phosphorylation site at codon 315. While there are differences between the germline and somatic mutations in terms of both the types and the frequency of mutations at specific codons/sites, the net effect in both cases is the generation of a truncated and probably nonfunctional or severely impaired protein.
Comparison of Mutational Spectra of Various Tumor Suppressor Genes With PTEN/MMAC1
Germline mutations in the PTEN/MMAC1 gene detected in the familial
Cowden's disease and Bannayan-Zonana syndrome as well as somatic
mutations in various tumors are distributed over the entire gene, with
a clustering in three regions, i.e., phosphorylation sites in exons 7
and 8 and particularly in the phosphatase core motif in exon 5 (Figs. 1
and 2). A great majority of these mutations, 62%-83%, are
made up of
frameshift, nonsense, and splice-site mutations, resulting in a
truncated protein, a feature in common with the mutational spectra of
other tumor suppressor genes. The germline mutations in BRCA1, BRCA2
(80), and patched (PTC) (93) genes are also
scattered
throughout these genes, and most are predicted to result in the
truncation of the proteins. In particular, in the case of BRCA2,
frameshift mutations constitute about 80% of the total mutations
(94,95). A high density of the somatic adenomatous polyposis
coli (APC) gene mutations occurs in the mutation cluster region,
whereas the germline mutations are scattered throughout the 5' half of
the gene (94). The mutational spectrum of the p53 gene is
unique in the sense that a vast majority of p53 mutations are missense
alterations (74%), with 22% of all mutations occurring in three hot
spots on amino acids 175, 248, and 273 (94,95). A
preponderance of missense mutations in the PTEN/MMAC1 gene (61 [41%]
of a total of 150 mutations) is observed only in glioblastomas. The
mutational spectrum of the PTEN/MMAC1 gene thus shares some common
features with other tumor suppressor genes, such as distribution of
mutations over the entire gene, clustering of mutations in three
important functional domains, i.e., the phosphatase core motif in exon
5 and phosphorylation sites in exons 7 and 8, and a large number of
missense mutations in some tumor types.
|
III. PTEN/MMAC1 AS TUMOR SUPPRESSOR WITH DEFINED ENZYMATIC FUNCTION |
|---|
|
TopAbstractIntroductionI. Germline PTEN/MMAC1 Mutations...II. Inactivation of PTEN/MMAC1...III. PTEN/MMAC1 as Tumor...NotesReferences |
|---|
Structural and functional conservation is a hallmark of tumor suppressor genes. PTEN/MMAC1 exhibits remarkable structural similarity across species. The human gene is highly similar to yeast, mouse, and dog sequences, with a virtual sequence identity at the amino acid level between human and mouse genes (1-3). The protein product of the gene appears to have lipid phosphatase activity dephosphorylating the second messenger PIP3 (101-103). In the nematode Caenorhabditis elegans, DAF-18, a homologue of PTEN/MMAC1 functions in the insulin receptor-like signaling pathway. The role of DAF-18 is probably to decrease second messenger signaling by PIP3, thereby regulating metabolism, development, and lifespan of the worm (96,97). The conservation of signaling pathways between the nematodes and mammals raises the possibility that human PTEN/MMAC1, by virtue of its ability to modulate the phosphorylation of the second messenger-PIP3, may play a role not only in cancer development but also in aging and metabolic diseases (96,97).
Phosphorylation and dephosphorylation are key regulatory mechanisms in a variety of fundamental cellular processes, including cellular proliferation and differentiation. A critical balance among these processes is maintained by protein kinases, which are widely implicated in carcinogenesis, and protein phosphatases, which are the natural antagonists of the action of normal as well as oncogenic protein kinases and have been associated with cell cycle regulation and inhibition of cell proliferation (98,99). PTEN/MMAC1 is the first tumor suppressor gene identified in the phosphatase family (100), and the principal function of its gene product appears to be dephosphorylation of the second-messenger PIP3 (101-103). The growth-inhibitory function of PTEN/MMAC1 is evident when its wild-type complementary DNA is transfected into a variety of cancer cell lines, including glioblastoma, melanoma, and renal, breast, and prostate carcinomas (104-111). Mutant forms of PTEN/MMAC1 that retain protein phosphatase but lose lipid phosphatase activity fail to suppress the growth of glioma cell lines (107,110). The same mutations have been detected in Cowden's disease patients as well as in various sporadic tumors, providing strong evidence that lipid phosphatase activity is essential for its role in normal development and its tumor suppressor function. The growth-suppressive activity of PTEN/MMAC1 may be cell type specific and mediated by multiple mechanisms. In some cell lines, growth is suppressed by the ability of PTEN/MMAC1 to block cell cycle progression at the G1 phase by causing an increased synthesis of cyclin-dependent kinase inhibitor p27Kip1 (110,112,113), whereas, in other tumor cell lines, PTEN/MMAC1 has been shown to directly induce apoptosis (programmed cell death) (107,111,114-116).
The results in knockout mutant mice also demonstrate that the PTEN/MMAC1 plays an important role in both embryonic development and tumor suppression. Three independent knockout studies using different deletions in the PTEN/MMAC1 gene and mice with different genetic backgrounds showed differences in the details, such as timing of embryonic lethality, in the phenotype and in the spectrum of the lesions (34-36). One study (34) reported hyperplastic/dysplastic changes in the prostate, skin, and colon of PTEN/MMAC1 heterozygotes, resembling the features characteristic of Cowden's disease and Bannayan-Zonana syndrome. Neoplasms in multiple organs, including prostate, thyroid, gastrointestinal tract, and endometrium, were reported in another study (36), with multifocal endometrial complex atypical hyperplasia developing in all heterozygous females. This situation closely resembles human endometrial cancer, where PTEN/MMAC1 is the most commonly mutated gene and is involved in the early events of endometrial tumorigenesis with more than 20% of complex atypical hyperplasia containing mutations in the gene (46,47). Although leukemia is not a feature of Cowden's disease, a high incidence of T-cell lymphoma/leukemia was reported in two knockout studies (35,36).
Cells derived from PTEN/MMAC1-deficient mouse embryos contain elevated levels of intracellular PIP3 supporting a role of PTEN/MMAC1 in this signaling pathway (116). The intracellular levels of PIP3 directly control the phosphorylation of protein kinase B/Akt protooncogene, which is one of the key regulatory molecules of cell survival in response to multiple apoptotic stimuli (117). In PTEN/MMAC1-deficient mouse embryo fibroblasts, constitutively elevated activity of PKB/Akt together with decreased sensitivity to apoptosis suggests a role for PTEN/MMAC1 as a negative regulator of cell survival (116). An inverse association between the PTEN/MMAC1 protein and AKT/PKB was also detected in cell lines derived from hematologic malignancies (118).
Besides regulating the intracellular PIP3 levels, the phosphatase activity of the PTEN/MMAC1 protein might impact other cellular substrates/functions. In addition to modulating signal transduction and cell cycle progression, phosphorylation affects other cellular processes, such as cell-cell and cell-matrix adhesion, migration, and angiogenesis, processes that are important not only for normal cellular physiology but also impact tumor growth, invasion, and metastasis. The cytoplasmic location of the PTEN/MMAC1 protein (3) and its homology with tensin, which binds to actin filaments at focal adhesions and is implicated in the assembly of the signaling complexes, suggest that its physiologic substrates may reside in the cytoplasm. That PTEN/MMAC1 may regulate cellular signals originating from the cytoskeleton and/or focal adhesions is suggested by its inhibitory effects on integrin-mediated cell spreading, formation of actin-containing microfilaments and focal adhesions, and cell migration (119,120). These biologic activities of PTEN/MMAC1, at least in vitro, appear to be arbitrated by tyrosine dephosphorylation of the focal adhesion kinase, and the phosphatase domain of the gene is required for these functions (119,120). Inactivation of the PTEN/MMAC1 in human cancers may, therefore, contribute not only to their proliferation but also to their invasive potential.
Although the PTEN/MMAC1 is inactivated in multiple advanced cancers, it does show selectivity for specific target organs, as suggested by the absence or relative infrequency of mutations in various tumors. The pathway involving PTEN/MMAC1, PI3 kinase, and PKB/Akt appears to be critical in regulating cell survival in various tissues. A detailed characterization of this pathway and identification of other physiologic substrate(s)/mechanism(s) of action of PTEN/MMAC1 will be helpful in understanding the signaling pathways that are subverted not only during the progression of advanced cancers like glioblastomas and prostate carcinomas but also during the initiation of a large subset of endometrial and ovarian carcinomas.
|
NOTES |
|---|
We thank Dr. Barbara Dunn for her critical comments on the manuscript.
|
REFERENCES |
|---|
|
TopAbstractIntroductionI. Germline PTEN/MMAC1 Mutations...II. Inactivation of PTEN/MMAC1...III. PTEN/MMAC1 as Tumor...NotesReferences |
|---|
1
Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, et
al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and
prostate cancer. Science 1997;275:1943-7.
2 Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon A, et al. Identification of a candidate tumor suppressor gene, MMAC1, at chromosome 10q, 1997.23.3 that is mutated in multiple advanced cancers. Nature Genet 1997;15:356-62.[CrossRef][Web of Science][Medline]
3
Li DM, Sun Hl. TEP1, encoded by a candidate tumor suppressor
locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor b. Cancer Res 1997;57:2130-6.
4
Hanssen AM, Fryns JP. Cowden syndrome. J Med Genet 1995;32:117-9.
5 Eng C. Cowden syndrome. J Genet Counsel 1997;6:181-91.[CrossRef]
6
Eng C, Murday V, Seal S, Mohammed S, Hodgson SV, Chaudary
MA, et al. Cowden syndrome and Lhermitte-Duclos disease in a family: a single genetic syndrome
with pleiotropy? J Med Genet 1994;31:458-61.
7 Ko FY, Wu TC, Hwang B. Intestinal polyps in children and adolescents: a review of 103 cases. Acta Paediatr 1995;36:197-202.
8
Fargnoli MC, Orlow SJ, Semelconcepcion J, Bolognia JL.
Clinicopathologic findings in the Banayan-Riley-Ruvalcaba syndrome. Arch Dermatol 1996;132:1214-8.
9 Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997;16:64-7.[CrossRef][Web of Science][Medline]cancerlit;97285123
10 Tsou HC, Teng DH, Ping XL, Brancolini V, Davis T, Hu R, et al. The role of MMAC1 mutations in early-onset breast cancer: causative in association with Cowden syndrome and excluded in BRCA1-negative cases. Am J Hum Genet 1997;61:1036-43.[CrossRef][Web of Science][Medline]cancerlit;98007985
11 Lynch ED, Ostermeyer EA, Lee MK, Arena JF, Ji H, Dann J, et al. Inherited mutations in PTEN that are associated with breast cancer, cowden disease, and juvenile polyposis. Am J Hum Genet 1997;61:1254-60.[CrossRef][Web of Science][Medline]cancerlit;98153621
12
Nelen MR, van Staveren WC, Peeters EA, Hassel MB, Gorlin
RJ, Hamm H, et al. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden
disease. Hum Mol Genet 1997;6:1383-7.
13 Marsh DJ, Dahia PL, Zheng Z, Liaw D, Parsons R, Gorlin RJ, et al. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet 1997;16:333-4.[CrossRef][Web of Science][Medline]cancerlit;97385233
14 Marsh DJ, Dahia PL, Coulon V, Zheng Z, Dorion-Bonnet, F, Call KM, et al. Allelic imbalance, including deletion of PTEN/MMAC1, at the Cowden disease locus on 10q22-23, in hamartomas from patients with Cowden syndrome and germline PTEN mutation. Genes Chromosomes Cancer 1998;21:61-9.[CrossRef][Web of Science][Medline]cancerlit;98105253
15
Marsh DJ, Coulon V, Lunetta KL, Rocca-Serra P, Dahia PL,
Zheng Z, et al. Mutation spectrum and genotype-phenotype analyses in Cowden disease and
Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet 1998;7:507-15.
16 Tsou HC, Ping XL, Xie XX, Gruener AC, Zhang HN, Nini R, et al. The genetic basis of Cowden's syndrome: three novel mutations in PTEN/MMAC1/TEP1. Hum Genet 1998;102:467-73.[CrossRef][Web of Science][Medline]cancerlit;98260873
17 Scala S, Bruni P, Lo Muzio L, Mignogna M, Viglietto G, Fusco A. Novel mutation of the PTEN gene in an Italian Cowden's disease kindred. Int J Oncol 1998;13:665-8.[Web of Science][Medline]cancerlit;98408002
18 Iida S, Nakamura Y, Fujii H, Kimura M, Moriwaki K. A heterozygous germline mutation of the PTEN/MMAC1 gene in a patient with Cowden disease. Int J Mol Med 1998;1:565-8.[Web of Science][Medline]cancerlit;99074455
19 Raizis AM, Ferguson MM, Robinson BA, Atkinson CH, George PM. Identification of a novel PTEN mutation (L139X) in a patient with Cowden disease and Sjogren's syndrome. Mol Pathol 1998;51:339-41.[Abstract]cancerlit;99209595
20 Stuphen R, Diamond TM, Minton SE, Peacocke M, Tsou HC, Root AW. Severe Lhermitte-Duclos disease with unique germline mutation of PTEN. Am J Med Genet 1999;82:290-3.[CrossRef][Web of Science][Medline]cancerlit;99158469
21 Koch R, Scholz M, Nelen MR, Schwechheimer K, Epplen JT, Harders AG, et al. Lhermitte-Duclos disease as a component of Cowden's syndrome. Case report and review of literature. J Neurosurg 1999;90:776-9.[Web of Science][Medline]cancerlit;99207969
22 Nelen MR, Kremer H, Konings IB, Schoute F, van Essen AJ, Koch R, et al. Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations. Eur J Hum Genet 1999;7:267-73.[CrossRef][Web of Science][Medline]cancerlit;99250761
23 Zori RT, Marsh DJ, Graham GE, Marliss EB, Eng C. Germline PTEN mutation in a family with Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome. Am J Med Genet 1998; 80: 399-402.[CrossRef][Web of Science][Medline]cancerlit;99072391
24
Celebi JT, Tsou HC, Chen FF, Zhang H, Ping XL, Lebwohl
MG, et al. Phenotypic findings of Cowden syndrome and Bannayan-Zonana syndrome in a family
associated with a single germline mutation in PTEN. J Med Genet 1999;36:360-4.
25 Tok Celebi J, Chen FF, Zhang H, Ping XL, Tsou HC, Peacocke M. Identification of PTEN mutations in five families with Bannayan-Zonana syndrome. Exp Dermatol 1999;8:134-9.[CrossRef][Web of Science][Medline]cancerlit;99247365
26 Olschwang, S, Serova-Sinilnikova OM, Lenoir GM, Thomas G. PTEN germ-line mutations in juvenile polyposis coli. Nat Genet 1998;18:12-4.[CrossRef][Web of Science][Medline]cancerlit;98085858
27
Marsh DJ, Roth S, Lunetta KL, Hemminki A, Dahia PL,
Sistonen P, et al. Exclusion of PTEN and 10q22-24 as the susceptibility locus for juvenile
polyposis syndrome. Cancer Res 1997;57:5017-21.
28 Eng C, Peacocke M. PTEN and inherited hamartoma-cancer syndromes. Nat Genet 1998;19:223.[CrossRef][Web of Science][Medline]cancerlit;98324769
29 Kurose K, Araki T, Matsunaka T, Takada Y, Emi M. Variant manifestation of Cowden disease in Japan: hamartomatous polyposis of the digestive tract with mutation of the PTEN gene. Am J Hum Genet 1999;64:308-10.[CrossRef][Web of Science][Medline]cancerlit;99115112
30 Howe JR, Ringold JC, Summers RW, Mitros FA, Nishimura DY, Stone EM. A gene for familial juvenile polyposis maps to chromosome 18q21.1. Am J Hum Genet 1998;62:1129-36.[CrossRef][Web of Science][Medline]cancerlit;98213578
31
Howe JR, Roth S, Ringold JC, Summers RW, Jarvinen HJ,
Sistonen P, et al. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science 1998;280:1086-8.
32
Carethers JM, Furnari FB, Zigman AF, Lavine JE, Jones MC,
Graham GE, et al. Absence of PTEN/MMAC1 germ-line mutations in sporadic
Bannayan-Riley-Ruvalcaba syndrome. Cancer Res 1998;58:2724-6.
33 DiCristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. Pten is essential for embryonic development and tumour suppression. Nat Genet 1998;19:348-55.[CrossRef][Web of Science][Medline]cancerlit;98361160
34 Suzuki A, de la Pompa JL, Stambolic V, Elia AJ, Sasaki T, del Barco Barrantes I, et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol 1998;8:1169-78.[CrossRef][Web of Science][Medline]cancerlit;99018257
35
Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M,
Yamada KM, et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A 1999; 96: 1563-8.
36
Aaltonen LA, Peltomaki P, Mecklin JP, Jarvinen H, Jass JR,
Green JS, et al. Replication errors in benign and malignant tumors from hereditary nonpolyposis
colorectal cancer patients. Cancer Res 1994;54:1645-8.
37
Duggan BD, Felix JC, Muderspach LI, Tourgeman D, Zheng J,
Shibata D. Microsatellite instability in sporadic endometrial carcinoma. J Natl Cancer Inst 1994;86:1216-21.
38 Enomoto T, Fujita M, Inoue M, Nomura T, Shroyer KR. Alteration of the p53 tumor suppressor gene and activation of c-K-ras-2 protooncogene in endometrial carcinoma from Colorado. Am J Clin Pathol 1995;103:224-30.[Web of Science][Medline]cancerlit;95159939
39 Tashiro H, Isacson C, Levine R, Kurman RJ, Cho KR, Hedrick L. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997;150:177-85.[Abstract]cancerlit;97158993
40
Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI, et al.
Mutations in PTEN are frequent in endometrial carcinoma but rare in other common
gynecological malignancies. Cancer Res 1997; 57: 3935-40.
41 Kong H, Suzuki A, Zou TT, Sakurada A, Kemp LW, Wakatsuki S, et al. PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet 1997;17:143-4.[CrossRef][Web of Science][Medline]cancerlit;97467720
42
Risinger JI, Hayes AK, Berchuck A, Barret JC. PTEN/MMAC1
mutations in endometrial cancers. Cancer Res 1997;57:4736-8.
43 Kurose K, Bando K, Fukino K, Sugisaki Y, Araki T, Emi M. Somatic mutations of the PTEN/MMAC1 gene in fifteen Japenese endometrial cancers: evidence for inactivation of both alleles. Jpn J Cancer Res 1998;89:842-8.[CrossRef][Web of Science][Medline]cancerlit;98438758
44 Simpkins SB, Peiffer-Schneider S, Mutch DG, Gersell D, Goodfellow PJ. PTEN mutations in endometrial cancers with 10q LOH: additional evidence for the involvement of multiple tumor suppressors. Gynecol Oncol 1998;71:391-5.[CrossRef][Web of Science][Medline]cancerlit;99106089
45 Risinger JI, Hayes K, Maxwell GL, Carney ME, Dodge RK, Barrett JC, et al. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res 1998;4:3005-10.[Abstract]cancerlit;99081511
46
Maxwell GL, Risinger JI, Gumbs C, Shaw H, Bentley RC,
Barrett C, et al. Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias. Cancer Res 1998;58:2500-3.
47
Levine RL, Cargile CB, Blazes MS, van Rees B, Kurman RJ,
Ellenson LH. PTEN mutations and microsatellite instability in complex atypical hyperplasia, a
precursor lesion to uterine endometrioid carcinoma. Cancer Res 1998;58:3254-8.
48 Ripley LS. Frameshift mutation: determinants of specificity. Annu Rev Genet 1990;24:189-213.[CrossRef][Web of Science][Medline]
49
Myeroff LL, Parson R, Kim SJ, Hedrick L, Cho KR, Orth K, et
al. A transforming growth factor beta receptor type II gene mutation common in colon and gastric
but rare in endometrial cancers with microsatellite instability. Cancer Res 1995;55:5545-7.
50 Louis DN, Gusella JF. A tiger behind many doors: multiple genetic pathways to malignant glioma. Trends Genet 1995;11:412-5.[CrossRef][Web of Science][Medline]cancerlit;96033652
51
Liu W, James CD, Frederick L, Alderete BE, Jenkins RB.
PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. Cancer Res 1997;57:5254-7.
52 Zhou XP, Li YJ, Hoang-Xuan K, Laurent-Puig P, Mokhtari K, Longy M, et al. Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations. Int J Cancer 1999;84:150-4.[CrossRef][Web of Science][Medline]cancerlit;99193911
53
Teng DH, Hu R, Lin H, Davis T, Iliev D, Frye C, et al.
MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 1997;57:5221-5.
54
Wang SI, Puc J, Li J, Bruce JN, Cairns P, Sidransky D, et al.
Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 1997;57:4183-6.
55
Rasheed BK, Stenzel TT, McLendon RE, Parsons R, Friedman
AH, Friedman HS, et al. PTEN gene mutations are seen in high-grade but not in low-grade
gliomas. Cancer Res 1997;57:4187-90.
56
Bostrom J, Cobbers JM, Wolter M, Tabatabai G, Weber RG,
Lichter P, et al. Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of
glioblastomas but not in meningiomas with loss of chromosome arm 10q. Cancer Res 1998;58:29-33.
57 Chiariello E, Roz L, Albarosa R, Magnani I, Finocchiaro G. PTEN/MMAC1 mutations in primary glioblastomas and short-term cultures of malignant gliomas.Oncogene 1998;16:541-5.[CrossRef][Web of Science][Medline]cancerlit;98143375
58 Fults D, Pedone CA, Thompson GE, Uchiyama CM, Gumpper KL, Iliev D, et al. Microsatellite deletion mapping on chromosome 10q and mutation analysis of MMAC1, FAS, and MXI1 in human glioblastoma multiforme. Int J Oncol 1998;12:905-10.[Web of Science][Medline]cancerlit;98168005
59 Duerr EM, Rollbrocker B, Hayashi Y, Peters N, Meyer-Puttlitz B, Louis DN, et al. PTEN mutations in gliomas and glioneuronal tumors. Oncogene1998 ;16:2259-64.[CrossRef][Web of Science][Medline]
60 Maier D, Zhang Z, Taylor E, Hamou MF, Gratzl O, Van Meir EG, et al. Somatic deletion mapping on chromosome 10 and sequence analysis of PTEN/MMAC1 point to the 10q25-26 region as the primary target in low-grade and high-grade gliomas. Oncogene 1998;16:3331-5.[CrossRef][Web of Science][Medline]cancerlit;98345158
61 Watanabe K, Peraud A, Gratas C, Wakai S, Kleihues P, Ohgaki H. p53 and PTEN gene mutations in gemistocytic astrocytomas. Acta Neuropathol (Berl) 1998;95:559-64.[CrossRef][Medline]
62 Tohma Y, Gratas C, Biernat W, Peraud A, Fukuda M, Yonekawa Y, et al. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J Neuropathol Exp Neurol 1998;57:684-9.[Web of Science][Medline]cancerlit;98352982
63 Davies MP, Gibbs FE, Halliwell N, Joyce KA, Roebuck MM, Rossi ML, et al. Mutation in the PTEN/MMAC1 gene in archival low grade and high grade gliomas. Br J Cancer 1999;79:1542-8.[CrossRef][Web of Science][Medline]cancerlit;99202787
64 Ichimura K, Schmidt EE, Myakawa A, Goike HM, Collins VP. Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor suppressor genes in the development of astrocytic gliomas of different malignancy grades. Genes Chromosomes Cancer 1998;22:9-15.[CrossRef][Web of Science][Medline]cancerlit;98252303
65 Mollenhauer J, Wiemann S, Scheurlen W, Korn B, Hayashi Y, Wilgenbus KK, et al. DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain tumours. Nat Genet 1997;17:32-9.[CrossRef][Web of Science][Medline]cancerlit;97434209
66
Dams E, Van de Kleft EJ, Martin JJ, Verlooy J, Willems PJ.
Instability of microsatellites in human gliomas. Cancer Res 1995;55:1547-9.
67
Wei Q, Bondy ML, Mao L, Guan Y, Cheng L, Cunningham J, et
al. Reduced expression of mismatch repair genes measured by multiplex reverse
transcription-polymerase chain reaction in human gliomas. Cancer Res 1997;57:1673-7.
68 Edelmann W, Yang K, Umar A, Heyer J, Lau K, Fan K, et al. Mutation in the mismatch repair gene Msh6 causes cancer susceptibility. Cell 1997;91:467-77.[CrossRef][Web of Science][Medline]cancerlit;98050922
69
Ittmann M. Allelic loss on chromosome 10 in prostate
adenocarcinoma. Cancer Res 1996;56:2143-7.
70
Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M,
Herman JG, et al. Frequent inactivation of TEN/MMAC1 in primary prostate cancer. Cancer Res 1997;57:4997-5000.
71
Suzuki H, Freije D, Nusskern DR, Okami K, Cairns P, Sidransky
D, et al. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic
prostate cancer tissues. Cancer Res 1998;58:204-9.
72 Feilotter HE, Nagai MA, Boag AH, Eng C, Mulligan LM. Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene 1998;16:1743-8.[CrossRef][Web of Science][Medline]cancerlit;98241178
73 Wang SI, Parsons R, Ittman M. Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. Clin Cancer Res 1998;4:811-5.[Abstract]cancerlit;98192222
74 Pesche S, Latil A, Muzeau F, Cussenot O, Fournier G, Longy M, et al. PTEN/MMAC1/TEP1 involvement in primary prostate cancers. Oncogene1998 ;16:2879-83.[CrossRef][Web of Science][Medline]
75
Whang YE, Wu X, Suzuki H, Reitter RE, Tran C, Vessella RL,
et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer
through loss of expression. Proc Natl Acad Sci U S A 1998;95:5246-50.
76
Obata K, Morland SJ, Watson RH, Hitchcock A,
Chenevix-Trench G, Thomas EJ, et al. Frequent PTEN/MMAC mutations in endometrioid but not
serous or mucinous epithelial ovarian tumors. Cancer Res 1998;58:2095-7.
77 Yokomizo A, Tindall DJ, Hartmann L, Jenkins RB, Smith DI, Liu W. Mutation analysis of the putative tumor suppressor PTEN/MMAC1 in human ovarian cancer. Int J Oncol 1998;13:101-5.[Web of Science][Medline]cancerlit;98290839
78
Rhei E, Kang L, Bogomolniy F, Federici MG, Borgen PI, Boyd
J. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast
carcinomas. Cancer Res 1997;57:3657-9.
79 Bose S, Wang SI, Terry MB, Hibshoosh H, Parsons R. Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas. Oncogene 1998;17:123-7.[CrossRef][Web of Science][Medline]cancerlit;98334396
80 Casey G. The BRCA1 and BRCA2 breast cancer genes. Curr Opin Oncol 1997;9:88-93 .[Medline]cancerlit;97245844
81
Dahia PL, Marsh DJ, Zheng Z, Zedenius J, Komminoth P, Frisk
T, et al. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid
tumors. Cancer Res 1997;57:4710-3.
82
Okami K, Wu L, Riggins G, Cairns P, Goggins M, Evron E, et
al. Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors. Cancer Res1998
;58:509-11.
83 Shao X, Tandon R, Samara G, Kanki H, Yano H, Close LG, et al. Mutational analysis of the PTEN gene in head and neck squamous cell carcinoma. Int J Cancer 1998;77:684-8.[CrossRef][Web of Science][Medline]cancerlit;98351585
84 Kohno T, Takahashi M, Manda R, Yokota J. Inactivation of the PTEN/MMAC1/TEP1 gene in human lung cancers. Gene Chromosomes Cancer 1998;22:152-6.
85 Petersen S, Rudolf J, Bockmuhl U, Gellert K, Wolf G, Dietel M, et al. Distinct regions of allelic imbalance on chromosome 10q22-q26 in squamous cell carcinomas of the lung. Oncogene 1998;17:449-54.[CrossRef][Web of Science][Medline]cancerlit;98359209
86 Yokomizo A, Tindall DJ, Drabkin H, Gemmill R, Franklin W, Yang P, et al. PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers. Oncogene 1998;17:475-9.[CrossRef][Web of Science][Medline]cancerlit;98359212
87 Tsao H, Zhang X, Benoit E, Haluska FG. Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene 1998;16:3397-402.[CrossRef][Web of Science][Medline]cancerlit;98355275
88 Nakahara Y, Nagai H, Kinoshita T, Uchida T, Hatano S, Murate R, et al. Mutational analysis of the PTEN/MMAC1 gene in non-Hodgkin's lymphoma. Leukemia 1998;12:1277-80.[CrossRef][Web of Science][Medline]cancerlit;98361349
89
Gronbaek K, Zeuthen J, Guldberg P, Ralfkiaer E, Hou-Jensen K.
Alterations of the MMAC1/PTEN gene in lymphoid malignancies. Blood 1998;91:4388-90.
90 Peters N, Wellenreuther R, Rollbrocker B, Hayashi Y, Meyer-Puttlitz B, Duerr EM, et al. Analysis of the PTEN gene in human meningiomas. Neuropathol App Neurobiol 1998;24:3-8.
91 Maxwell GL, Risinger JI, Tong B, Shaw H, Barrett JC, Berchuck A, et al. Mutation of the PTEN tumor suppressor gene is not a feature of ovarian cancers. Gynecol Oncol 1998;70:13-6.[CrossRef][Web of Science][Medline]cancerlit;98375526
92 Bird AP. The relationship of DNA methylation to cancer. Cancer Surv 1996;28:87-101.[Web of Science][Medline]cancerlit;97131378
93
Chidambaram A, Goldstein AM, Gailani MR, Gerrard B, Bale
SJ, DiGiovanna JJ, et al. Mutations in the human homologue of the Drosophila patched
gene in Caucasian and African-American nevoid basal cell carcinoma syndrome patients. Cancer Res 1996;56:4599-601.
94
Beroud C, Soussi T. p53 and APC gene mutations: software and
databases. Nucleic Acids Res 1997;25:138.
95
Hussain SP, Harris CC. Molecular epidemiology of human
cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer Res 1998;58:4023-37.
96 Ogg S, Ruvkun G. The C. elegans PTEN homolog, DAF-18, acts in the insulin receptor-like metabolic signaling pathway. Mol Cell 1998;2:887-93.[CrossRef][Web of Science][Medline]cancerlit;99102962
97
Gil EB, Malone Link E, Liu LX, Johnson CD, Lees JA.
Regulation of the insulin-like developmental pathway of Caenorhabditis elegans by a
homolog of the PTEN tumor suppressor gene. Proc Natl Acad Sci U S A 1999;96:2925-30.
98 Sun H, Tonks NK. The coordinated action of protein tyrosine phosphatases and kinases in cell signaling. Trends Biochem Sci 1994;19:480-5.[CrossRef][Web of Science][Medline]
99 Parsons R. Phosphatases and tumorigenesis. Curr Opin Oncol 1998;10:88-91.[Medline]cancerlit;98125966
100
Meyers MP, Stolarov JP, Eng C, Li J, Wang SI, Wigler MH, et
al. P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity
phosphatase. Proc Natl Acad Sci U S A 1997;94: 9052-7.
101
Maehama T, Dixon JE. The tumor suppressor,
PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphotidylinositol
3,4,5-triphosphate. J Biol Chem 1998;273:13375-8.
102
Cantley LC, Neel BG. New insights into tumor suppression:
PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A 1999;96:4240-5.
103 Maehama T, Dixon JE. PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol 1999;9:125-8.[CrossRef][Web of Science][Medline]cancerlit;99221952
104
Furnari FB, Lin H, Huang HS, Cavenee WK. Growth
suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc Natl Acad Sci U S A 1997;94:12479-84.
105
Cheney IW, Johnson DE, Vaillancourt MT, Avanzini J,
Morimoto A, Demers GW, et al. Suppression of tumorigenicity of glioblastoma cells by
adenovirus-mediated MMAC1/PTEN gene transfer. Cancer Res 1998;58:2331-4.
106 Haas-Kogan D, Shalev N, Wong M, Mills G, Yount G, Stokoe D. Protein kinase B (PKB/AKT) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol 1998;8:1195-8.[CrossRef][Web of Science][Medline]cancerlit;99018262
107
Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP,
Hemmings BA, et al. The lipid phosphatase activity of PTEN is critical for its tumor supressor
function. Proc Natl Acad Sci U S A 1998;95:13513-8.
108
Robertson GP, Furnari FB, Miele ME, Glendening MJ, Welch
DR, Fountain JW, et al. In vitro loss of heterozygosity targets the PTEN/MMAC1 gene
in melanoma. Proc Natl Acad Sci U S A 1998;95:9418-23.
109
Davies MA, Lu Y, Sano T, Fang X, Tang P, LaPushin R, et al.
Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Aktactivation
and induces anoikis. Cancer Res 1998;58:5285-90.
110
Furnari FB, Huang HJ, Cavenee WK. The phosphoinositol
phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. Cancer Res 1998;58:5002-8.
111
Davies MA, Koul D, Dhesi H, Berman R, McDonnell TJ,
McConkey D, et al. Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate
carcinoma cells by MMAC/PTEN. Cancer Res 1999;59:2551-6.
112
Li DM, Sun H. PTEN/MMAC1/TEP1 suppresses the
tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl
Acad Sci U S A 1998;95:15406-11.
113
Cheney IW, Neuteboom ST, Vaillancourt MT, Ramachandra
M, Bookstein R. Adenovirus-mediated gene transfer of MMAC1/PTEN to glioblastoma cells
inhibits S phase entry by the recruitment of p27 Kip1 into cyclin E/CDK2
complexes. Cancer Res 1999;59:2318-23.
114
Li J, Simpson L, Takahashi M, Miliaresis C, Myers MP, Tonks
N, et al. The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the
AKT/protein kinase B oncogene. Cancer Res 1998;58:5667-72.
115
Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL. The
PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the
phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 1998;95:15587-91.
116 Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998;95:29-39.[CrossRef][Web of Science][Medline]cancerlit;98449694
117 Downward, J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 1998;10:262-7.[CrossRef][Web of Science][Medline]cancerlit;98222664
118
Dahia PL, Aguiar RC, Alberta J, Kum JB, Caron S, Sill H, et
al. PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via
multiple mechanisms in haematological malignancies. Hum Mol Genet 1999;8:185-93.
119
Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada
KM. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 1998;280:1614-7.
120
Tamura M, Gu J, Takino T, Yamada KM. Tumor suppressor
PTEN inhibition of cell invasion, migration, and growth: differential involvement of focal adhesion
kinase and p130cas. Cancer Res 1999;59:442-9.
Manuscript received February 23, 1999; revised August 13, 1999; accepted September 21, 1999.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Mosessian, N. K. Avliyakulov, D. J. Mulholland, P. Boontheung, J. A. Loo, and H. Wu Analysis of PTEN Complex Assembly and Identification of Heterogeneous Nuclear Ribonucleoprotein C as a Component of the PTEN-associated Complex J. Biol. Chem., October 30, 2009; 284(44): 30159 - 30166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Normanno, A. Morabito, A. De Luca, M. C. Piccirillo, M. Gallo, M. R Maiello, and F. Perrone Target-based therapies in breast cancer: current status and future perspectives Endocr. Relat. Cancer, September 1, 2009; 16(3): 675 - 702. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A.T. Hildebrandt, H. Yang, M.-C. Hung, J. G. Izzo, M. Huang, J. Lin, J. A. Ajani, and X. Wu Genetic Variations in the PI3K/PTEN/AKT/mTOR Pathway Are Associated With Clinical Outcomes in Esophageal Cancer Patients Treated With Chemoradiotherapy J. Clin. Oncol., February 20, 2009; 27(6): 857 - 871. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Zhou, J. Blundell, S. Ogawa, C.-H. Kwon, W. Zhang, C. Sinton, C. M. Powell, and L. F. Parada Pharmacological Inhibition of mTORC1 Suppresses Anatomical, Cellular, and Behavioral Abnormalities in Neural-Specific Pten Knock-Out Mice J. Neurosci., February 11, 2009; 29(6): 1773 - 1783. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Ma, W. Fu, P. Li, S. V. Nicosia, G. Jenster, X. Zhang, and W. Bai FoxO1 Mediates PTEN Suppression of Androgen Receptor N- and C-Terminal Interactions and Coactivator Recruitment Mol. Endocrinol., February 1, 2009; 23(2): 213 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Radziszewska, D. Choi, K.-T. T. Nguyen, S. A. Schroer, P. Tajmir, L. Wang, A. Suzuki, T. W. Mak, G. I. Evan, and M. Woo PTEN Deletion and Concomitant c-Myc Activation Do Not Lead to Tumor Formation in Pancreatic {beta} Cells J. Biol. Chem., January 30, 2009; 284(5): 2917 - 2922. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-J. Chang, D. J. Mulholland, B. Valamehr, S. Mosessian, W. R. Sellers, and H. Wu PTEN Nuclear Localization Is Regulated by Oxidative Stress and Mediates p53-Dependent Tumor Suppression Mol. Cell. Biol., May 15, 2008; 28(10): 3281 - 3289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-H. Kwon, D. Zhao, J. Chen, S. Alcantara, Y. Li, D. K. Burns, R. P. Mason, E. Y.-H. P. Lee, H. Wu, and L. F. Parada Pten Haploinsufficiency Accelerates Formation of High-Grade Astrocytomas Cancer Res., May 1, 2008; 68(9): 3286 - 3294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-J. Choi, T.-W. Chung, S.-J. Kim, S.-Y. Cho, Y.-S. Lee, Y.-C. Lee, J.-H. Ko, and C.-H. Kim The AP-2{alpha} transcription factor is required for the ganglioside GM3-stimulated transcriptional regulation of a PTEN gene Glycobiology, May 1, 2008; 18(5): 395 - 407. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. A. Fritz, T.-M. Lin, and R. E. Peterson The aryl hydrocarbon receptor (AhR) inhibits vanadate-induced vascular endothelial growth factor (VEGF) production in TRAMP prostates Carcinogenesis, May 1, 2008; 29(5): 1077 - 1082. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. K. Ratnacaram, M. Teletin, M. Jiang, X. Meng, P. Chambon, and D. Metzger Temporally controlled ablation of PTEN in adult mouse prostate epithelium generates a model of invasive prostatic adenocarcinoma PNAS, February 19, 2008; 105(7): 2521 - 2526. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Crowell, V. E. Steele, and J. R. Fay Targeting the AKT protein kinase for cancer chemoprevention Mol. Cancer Ther., August 1, 2007; 6(8): 2139 - 2148. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Kopelovich, J. R. Fay, C. C. Sigman, and J. A. Crowell The Mammalian Target of Rapamycin Pathway as a Potential Target for Cancer Chemoprevention Cancer Epidemiol. Biomarkers Prev., July 1, 2007; 16(7): 1330 - 1340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z Wu, K. McRoberts, and D Theodorescu The role of PTEN in prostate cancer cell tropism to the bone micro-environment Carcinogenesis, July 1, 2007; 28(7): 1393 - 1400. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. McEwan, V. G. Brunton, G. S. Baillie, N. R. Leslie, M. D. Houslay, and M. C. Frame Chemoresistant KM12C Colon Cancer Cells Are Addicted to Low Cyclic AMP Levels in a Phosphodiesterase 4-Regulated Compartment via Effects on Phosphoinositide 3-Kinase Cancer Res., June 1, 2007; 67(11): 5248 - 5257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Okahara, K. Itoh, A. Nakagawara, M. Murakami, Y. Kanaho, and T. Maehama Critical Role of PICT-1, a Tumor Suppressor Candidate, in Phosphatidylinositol 3,4,5-Trisphosphate Signals and Tumorigenic Transformation Mol. Biol. Cell, November 1, 2006; 17(11): 4888 - 4895. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Pankow, C. Bamberger, A. Klippel, and S. Werner Regulation of epidermal homeostasis and repair by phosphoinositide 3-kinase J. Cell Sci., October 1, 2006; 119(19): 4033 - 4046. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hidalgo, J. C. Buckner, C. Erlichman, M. S. Pollack, J. P. Boni, G. Dukart, B. Marshall, L. Speicher, L. Moore, and E. K. Rowinsky A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer. Clin. Cancer Res., October 1, 2006; 12(19): 5755 - 5763. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Packer, S. Pavey, A. Parker, M. Stark, P. Johansson, B. Clarke, P. Pollock, M. Ringner, and N. Hayward Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN Carcinogenesis, September 1, 2006; 27(9): 1778 - 1786. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Vilgelm, Z. Lian, H. Wang, S. L. Beauparlant, A. Klein-Szanto, L. H. Ellenson, and A. Di Cristofano Akt-Mediated Phosphorylation and Activation of Estrogen Receptor {alpha} Is Required for Endometrial Neoplastic Transformation in Pten+/- Mice. Cancer Res., April 1, 2006; 66(7): 3375 - 3380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Granville, R. M. Memmott, J. J. Gills, and P. A. Dennis Handicapping the Race to Develop Inhibitors of the Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway Clin. Cancer Res., February 1, 2006; 12(3): 679 - 689. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. DeFeo-Jones, S. F. Barnett, S. Fu, P. J. Hancock, K. M. Haskell, K. R. Leander, E. McAvoy, R. G. Robinson, M. E. Duggan, C. W. Lindsley, et al. Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members Mol. Cancer Ther., February 1, 2005; 4(2): 271 - 279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. R. Camp, J. Summy, T. W. Bauer, W. Liu, G. E. Gallick, and L. M. Ellis Molecular Mechanisms of Resistance to Therapies Targeting the Epidermal Growth Factor Receptor Clin. Cancer Res., January 1, 2005; 11(1): 397 - 405. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Fraser, X. Zhu, C.-H. Kwon, E. J. Uhlmann, D. H. Gutmann, and S. J. Baker Pten Loss Causes Hypertrophy and Increased Proliferation of Astrocytes In vivo Cancer Res., November 1, 2004; 64(21): 7773 - 7779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Okahara, H. Ikawa, Y. Kanaho, and T. Maehama Regulation of PTEN Phosphorylation and Stability by a Tumor Suppressor Candidate Protein J. Biol. Chem., October 29, 2004; 279(44): 45300 - 45303. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Thompson and C. B. Thompson Putting the Rap on Akt J. Clin. Oncol., October 15, 2004; 22(20): 4217 - 4226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Hagenbeek, M. Naspetti, F. Malergue, F. Garcon, J. A. Nunes, K. B.J.M. Cleutjens, J. Trapman, P. Krimpenfort, and H. Spits The Loss of PTEN Allows TCR {alpha}{beta} Lineage Thymocytes to Bypass IL-7 and Pre-TCR-mediated Signaling J. Exp. Med., October 4, 2004; 200(7): 883 - 894. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Spaner Amplifying cancer vaccine responses by modifying pathogenic gene programs in tumor cells J. Leukoc. Biol., August 1, 2004; 76(2): 338 - 351. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. H. Min, J.-W. Cheong, M. H. Lee, J. Y. Kim, S. T. Lee, J. S. Hahn, and Y. W. Ko Elevated S-Phase Kinase-Associated Protein 2 Protein Expression in Acute Myelogenous Leukemia: Its Association with Constitutive Phosphorylation of Phosphatase and Tensin Homologue Protein and Poor Prognosis Clin. Cancer Res., August 1, 2004; 10(15): 5123 - 5130. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Sansal and W. R. Sellers The Biology and Clinical Relevance of the PTEN Tumor Suppressor Pathway J. Clin. Oncol., July 15, 2004; 22(14): 2954 - 2963. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Li, H. Chen, M.-S. Tang, X. Shi, S. Amin, D. Desai, M. Costa, and C. Huang PI-3K and Akt are mediators of AP-1 induction by 5-MCDE in mouse epidermal Cl41 cells J. Cell Biol., April 12, 2004; 165(1): 77 - 86. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Huang, D. C. Muddiman, and D. J. Tindall Androgens Negatively Regulate Forkhead Transcription Factor FKHR (FOXO1) through a Proteolytic Mechanism in Prostate Cancer Cells J. Biol. Chem., April 2, 2004; 279(14): 13866 - 13877. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Backman, D. Ghazarian, K. So, O. Sanchez, K.-U. Wagner, L. Hennighausen, A. Suzuki, M.-S. Tsao, W. B. Chapman, V. Stambolic, et al. Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten PNAS, February 10, 2004; 101(6): 1725 - 1730. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Xing Cui, Song Li, A. Shraim, Y. Kobayashi, T. Hayakawa, S. Kanno, M. Yamamoto, and S. Hirano Subchronic Exposure to Arsenic Through Drinking Water Alters Expression of Cancer-Related Genes in Rat Liver Toxicol Pathol, January 1, 2004; 32(1): 64 - 72. [Abstract] [PDF]
|
|
|
|
|
|
C. E. Barbieri, C. E. Barton, and J. A. Pietenpol {Delta}Np63{alpha} Expression Is Regulated by the Phosphoinositide 3-Kinase Pathway J. Biol. Chem., December 19, 2003; 278(51): 51408 - 51414. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-H. Kwon, X. Zhu, J. Zhang, and S. J. Baker mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo PNAS, October 28, 2003; 100(22): 12923 - 12928. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jetzt, J. A. Howe, M. T. Horn, E. Maxwell, Z. Yin, D. Johnson, and C. C. Kumar Adenoviral-Mediated Expression of a Kinase-Dead Mutant of Akt Induces Apoptosis Selectively in Tumor Cells and Suppresses Tumor Growth in Mice Cancer Res., October 15, 2003; 63(20): 6697 - 6706. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Guzeloglu-Kayisli, U. A. Kayisli, R. Al-Rejjal, W. Zheng, G. Luleci, and A. Arici Regulation of PTEN (Phosphatase and Tensin Homolog Deleted on Chromosome 10) Expression by Estradiol and Progesterone in Human Endometrium J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 5017 - 5026. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. J. Halvorsen, S. A. Haukaas, and L. A. Akslen Combined Loss of PTEN and p27 Expression Is Associated with Tumor Cell Proliferation by Ki-67 and Increased Risk of Recurrent Disease in Localized Prostate Cancer Clin. Cancer Res., April 1, 2003; 9(4): 1474 - 1479. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Pei, Y. Peng, Y. Yang, X. B. Ling, W. G. van Eyndhoven, K. C. Q. Nguyen, M. Rubin, T. Hoey, S. Powers, and J. Li PRC17, a Novel Oncogene Encoding a Rab GTPase-activating Protein, Is Amplified in Prostate Cancer Cancer Res., October 1, 2002; 62(19): 5420 - 5424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. B. Knobbe, A. Merlo, and G. Reifenberger Pten signaling in gliomas Neuro-oncol, July 1, 2002; 4(3): 196 - 211. [Abstract] [PDF]
|
|
|
|
 |
|
 R. A. Levine, T. Forest, and C. Smith Tumor Suppressor PTEN is Mutated in Canine Osteosarcoma Cell Lines and Tumors Vet. Pathol., May 1, 2002; 39(3): 372 - 378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Soria, H.-Y. Lee, J. I. Lee, L. Wang, J.-P. Issa, B. L. Kemp, D. D. Liu, J. M. Kurie, L. Mao, and F. R. Khuri Lack of PTEN Expression in Non-Small Cell Lung Cancer Could Be Related to Promoter Methylation Clin. Cancer Res., May 1, 2002; 8(5): 1178 - 1184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Firestein and M. L. Cleary Pseudo-phosphatase Sbf1 contains an N-terminal GEF homology domain that modulates its growth regulatory properties J. Cell Sci., March 10, 2002; 114(16): 2921 - 2927. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Gupta, W. G. McKenna, C. N. Weber, M. D. Feldman, J. D. Goldsmith, R. Mick, M. Machtay, D. I. Rosenthal, V. J. Bakanauskas, G. J. Cerniglia, et al. Local Recurrence in Head and Neck Cancer: Relationship to Radiation Resistance and Signal Transduction Clin. Cancer Res., March 1, 2002; 8(3): 885 - 892. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. I. Lee, J.-C. Soria, K. A. Hassan, A. K. El-Naggar, X. Tang, D. D. Liu, W. K. Hong, and L. Mao Loss of PTEN Expression as a Prognostic Marker for Tongue Cancer Arch Otolaryngol Head Neck Surg, December 1, 2001; 127(12): 1441 - 1445. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Grossmann, H. Huang, and D. J. Tindall Androgen Receptor Signaling in Androgen-Refractory Prostate Cancer J Natl Cancer Inst, November 21, 2001; 93(22): 1687 - 1697. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Huang, J. C. Cheville, Y. Pan, P. C. Roche, L. J. Schmidt, and D. J. Tindall PTEN Induces Chemosensitivity in PTEN-mutated Prostate Cancer Cells by Suppression of Bcl-2 Expression J. Biol. Chem., October 12, 2001; 276(42): 38830 - 38836. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Kwabi-Addo, D. Giri, K. Schmidt, K. Podsypanina, R. Parsons, N. Greenberg, and M. Ittmann Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression PNAS, September 5, 2001; (2001) 201167798. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Minaguchi, H. Yoshikawa, K. Oda, T. Ishino, T. Yasugi, T. Onda, S. Nakagawa, K. Matsumoto, K. Kawana, and Y. Taketani PTEN Mutation Located Only Outside Exons 5, 6, and 7 Is an Independent Predictor of Favorable Survival in Endometrial Carcinomas Clin. Cancer Res., September 1, 2001; 7(9): 2636 - 2642. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Smith, I. Tachibana, S. M. Passe, B. K. Huntley, T. J. Borell, N. Iturria, J. R. O'Fallon, P. L. Schaefer, B. W. Scheithauer, C. D. James, et al. PTEN Mutation, EGFR Amplification, and Outcome in Patients With Anaplastic Astrocytoma and Glioblastoma Multiforme J Natl Cancer Inst, August 15, 2001; 93(16): 1246 - 1256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Neshat, I. K. Mellinghoff, C. Tran, B. Stiles, G. Thomas, R. Petersen, P. Frost, J. J. Gibbons, H. Wu, and C. L. Sawyers Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR PNAS, August 10, 2001; (2001) 171076798. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Podsypanina, R. T. Lee, C. Politis, I. Hennessy, A. Crane, J. Puc, M. Neshat, H. Wang, L. Yang, J. Gibbons, et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice PNAS, August 10, 2001; (2001) 171060098. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Ringel, N. Hayre, J. Saito, B. Saunier, F. Schuppert, H. Burch, V. Bernet, K. D. Burman, L. D. Kohn, and M. Saji Overexpression and Overactivation of Akt in Thyroid Carcinoma Cancer Res., August 1, 2001; 61(16): 6105 - 6111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B.-H. Jiang, G. Jiang, J. Z. Zheng, Z. Lu, T. Hunter, and P. K. Vogt Phosphatidylinositol 3-Kinase Signaling Controls Levels of Hypoxia-inducible Factor 1 Cell Growth Differ., July 1, 2001; 12(7): 363 - 369. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Simpson, J. Li, D. Liaw, I. Hennessy, J. Oliner, F. Christians, and R. Parsons PTEN Expression Causes Feedback Upregulation of Insulin Receptor Substrate 2 Mol. Cell. Biol., June 15, 2001; 21(12): 3947 - 3958. [Abstract] [Full Text]
|
|
|
|
|
|
K. L. Nathanson, R. Omaruddin, S. B. Malkowicz, and T. R. Rebbeck An Intronic Variant in PTEN Is Not Associated with Prostate Cancer Risk Cancer Epidemiol. Biomarkers Prev., March 1, 2001; 10(3): 277 - 278. [Full Text]
|
|
|
|
|
|
N. Prasad, R. S. Topping, and S. J. Decker SH2-Containing Inositol 5'-Phosphatase SHIP2 Associates with the p130Cas Adapter Protein and Regulates Cellular Adhesion and Spreading Mol. Cell. Biol., February 15, 2001; 21(4): 1416 - 1428. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. Tian, L. C. Brody, S. Fan, Z. Huang, and J. P. Landers Capillary and Microchip Electrophoresis for Rapid Detection of Known Mutations by Combining Allele-specific DNA Amplification with Heteroduplex Analysis Clin. Chem., February 1, 2001; 47(2): 173 - 185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-T. Dong, C.-L. Li, T. W. Sipe, and H. F. Frierson Jr. Mutations of PTEN/MMAC1 in Primary Prostate Cancers from Chinese Patients Clin. Cancer Res., February 1, 2001; 7(2): 304 - 308. [Abstract] [Full Text]
|
|
|
|
|
|
K. M. Yamada and M. Araki Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis J. Cell Sci., January 7, 2001; 114(13): 2375 - 2382. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Aoki, E. Blazek, and P. K. Vogt A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt PNAS, December 22, 2000; (2000) 11528498. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. Schondorf, A. Dostal, J. Grabmann, and U.-J. Gohring Single Mutations of the PTEN Gene in Recurrent Ovarian Carcinomas Reproductive Sciences, September 1, 2000; 7(5): 313 - 316. [Abstract] [PDF]
|
|
|
|
|
|
A. H. Holway, K. M. Rieger-Christ, W. R. Miner, J. W. Cain, J. M. Dugan, J. A. Pezza, M. L. Silverman, A. Shapter, R. McLellan, and I. C. Summerhayes Somatic Mutation of PTEN in Vulvar Cancer Clin. Cancer Res., August 1, 2000; 6(8): 3228 - 3235. [Abstract] [Full Text]
|
|
|
|
|
|
C.-Y. Shen, J.-C. Yu, Y.-L. Lo, C.-H. Kuo, C.-T. Yue, Y.-S. Jou, C.-S. Huang, J.-C. Lung, and C.-W. Wu Genome-wide Search for Loss of Heterozygosity Using Laser Capture Microdissected Tissue of Breast Carcinoma: An Implication for Mutator Phenotype and Breast Cancer Pathogenesis Cancer Res., July 1, 2000; 60(14): 3884 - 3892. [Abstract] [Full Text]
|
|
|
|
|
|
I. U. Ali Gatekeeper for Endometrium: the PTEN Tumor Suppressor Gene J Natl Cancer Inst, June 7, 2000; 92(11): 861 - 863. [Full Text] [PDF]
|
|
|
|
|
|
X. Wu, K. Hepner, S. Castelino-Prabhu, D. Do, M. B. Kaye, X.-J. Yuan, J. Wood, C. Ross, C. L. Sawyers, and Y. E. Whang Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2 PNAS, April 11, 2000; 97(8): 4233 - 4238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Matias-Guiu, E. Bussaglia, L. Catasus, H. Lagarda, E. Gras, P. Machin, J. Prat, W. M. Lin, and C. Y. Muller Correspondence re: W. M. Lin et al., Loss of Heterozygosity and Mutational Analysis of the PTEN/MMAC1 Gene in Synchronous Endometrial and Ovarian Carcinomas. Clin. Cancer Res., 4: 2577-2583, 1998. Clin. Cancer Res., April 1, 2000; 6(4): 1598 - 1600. [Full Text]
|
|
|
|
|
|
G. Schwartzbauer and J. Robbins The Tumor Suppressor Gene PTEN Can Regulate Cardiac Hypertrophy and Survival J. Biol. Chem., September 14, 2001; 276(38): 35786 - 35793. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Aoki, E. Blazek, and P. K. Vogt A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt PNAS, January 2, 2001; 98(1): 136 - 141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. You, D. H. Castrillon, B. C. Bastian, R. C. O'Hagan, M. W. Bosenberg, R. Parsons, L. Chin, and R. A. DePinho Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice PNAS, February 5, 2002; 99(3): 1455 - 1460. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Podsypanina, R. T. Lee, C. Politis, I. Hennessy, A. Crane, J. Puc, M. Neshat, H. Wang, L. Yang, J. Gibbons, et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice PNAS, August 28, 2001; 98(18): 10320 - 10325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Neshat, I. K. Mellinghoff, C. Tran, B. Stiles, G. Thomas, R. Petersen, P. Frost, J. J. Gibbons, H. Wu, and C. L. Sawyers Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR PNAS, August 28, 2001; 98(18): 10314 - 10319. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Kwabi-Addo, D. Giri, K. Schmidt, K. Podsypanina, R. Parsons, N. Greenberg, and M. Ittmann Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression PNAS, September 25, 2001; 98(20): 11563 - 11568. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||